Hepion Pharmaceuticals (HEPA) Competitors $0.06 -0.01 (-8.12%) As of 08/14/2025 03:36 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HEPA vs. ONCO, ADXS, GRTX, PTIX, AKAN, SHPH, TNFA, SCNI, ATXI, and CDTShould you be buying Hepion Pharmaceuticals stock or one of its competitors? The main competitors of Hepion Pharmaceuticals include Onconetix (ONCO), Ayala Pharmaceuticals (ADXS), Galera Therapeutics (GRTX), Atrinsic (PTIX), Akanda (AKAN), Shuttle Pharmaceuticals (SHPH), TNF Pharmaceuticals (TNFA), Scinai Immunotherapeutics (SCNI), Avenue Therapeutics (ATXI), and Conduit Pharmaceuticals (CDT). These companies are all part of the "pharmaceutical products" industry. Hepion Pharmaceuticals vs. Its Competitors Onconetix Ayala Pharmaceuticals Galera Therapeutics Atrinsic Akanda Shuttle Pharmaceuticals TNF Pharmaceuticals Scinai Immunotherapeutics Avenue Therapeutics Conduit Pharmaceuticals Onconetix (NASDAQ:ONCO) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation. Do insiders and institutionals hold more shares of ONCO or HEPA? 23.9% of Onconetix shares are held by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are held by institutional investors. 3.1% of Onconetix shares are held by insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media favor ONCO or HEPA? In the previous week, Onconetix had 3 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 4 mentions for Onconetix and 1 mentions for Hepion Pharmaceuticals. Hepion Pharmaceuticals' average media sentiment score of 1.00 beat Onconetix's score of 0.34 indicating that Hepion Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Onconetix Neutral Hepion Pharmaceuticals Positive Which has better valuation and earnings, ONCO or HEPA? Hepion Pharmaceuticals has lower revenue, but higher earnings than Onconetix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOnconetix$2.52M0.65-$58.69MN/AN/AHepion PharmaceuticalsN/AN/A-$48.93M-$219.000.00 Which has more risk & volatility, ONCO or HEPA? Onconetix has a beta of 3.37, indicating that its share price is 237% more volatile than the S&P 500. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500. Is ONCO or HEPA more profitable? Hepion Pharmaceuticals has a net margin of 0.00% compared to Onconetix's net margin of -2,913.71%. Onconetix's return on equity of -514.04% beat Hepion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Onconetix-2,913.71% -514.04% -75.82% Hepion Pharmaceuticals N/A -812.56%-207.31% SummaryOnconetix beats Hepion Pharmaceuticals on 7 of the 10 factors compared between the two stocks. Get Hepion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HEPA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HEPA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HEPA vs. The Competition Export to ExcelMetricHepion PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$686K$791.77M$5.61B$9.84BDividend YieldN/A4.84%4.61%4.07%P/E Ratio-0.011.1830.2925.74Price / SalesN/A26.06463.41115.83Price / CashN/A19.5638.2159.48Price / Book0.056.588.826.15Net Income-$48.93M-$4.98M$3.25B$265.06M7 Day PerformanceN/A1.86%3.70%2.60%1 Month PerformanceN/A0.45%5.84%2.83%1 Year PerformanceN/A16.14%29.92%25.58% Hepion Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HEPAHepion Pharmaceuticals1.1675 of 5 stars$0.06-8.1%N/A-99.8%$686KN/A-0.0120Positive NewsShort Interest ↓Gap UpONCOOnconetix0.9358 of 5 stars$3.17-8.1%N/A-99.4%$1.84M$2.52M0.0012Earnings ReportShort Interest ↓Gap DownADXSAyala PharmaceuticalsN/A$0.03-13.5%N/A+168.0%$1.71M$3.24M0.0020Gap DownGRTXGalera TherapeuticsN/A$0.02-2.2%N/A-69.0%$1.70MN/A-0.0630PTIXAtrinsic1.0064 of 5 stars$2.69-1.1%N/A-65.5%$1.60MN/A-0.212AKANAkanda0.9793 of 5 stars$1.07-2.7%N/A-54.4%$1.57M$836.66K0.00110Short Interest ↑Gap DownSHPHShuttle Pharmaceuticals1.7114 of 5 stars$3.63+3.7%N/A-92.9%$1.54MN/A-0.875News CoverageNegative NewsShort Interest ↓Gap DownTNFATNF PharmaceuticalsN/A$0.11+5.7%N/AN/A$1.52MN/A-0.026Upcoming EarningsGap UpSCNIScinai Immunotherapeutics0.9349 of 5 stars$1.51+2.7%N/A-50.8%$1.47M$660K-0.1620Upcoming EarningsShort Interest ↑Gap DownATXIAvenue Therapeutics1.649 of 5 stars$0.46+1.1%N/A-78.8%$1.46MN/A0.034CDTConduit Pharmaceuticals0.2058 of 5 stars$1.88+4.4%N/A-99.3%$1.44MN/A0.003Earnings ReportShort Interest ↑Gap Up Related Companies and Tools Related Companies ONCO Alternatives ADXS Alternatives GRTX Alternatives PTIX Alternatives AKAN Alternatives SHPH Alternatives TNFA Alternatives SCNI Alternatives ATXI Alternatives CDT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HEPA) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hepion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hepion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access